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Abstract
Background: People with Parkinson’s disease (PD) commonly experience postural instability, resulting in poor
balance and an increased risk of falls. Exercise-based video gaming (exergaming) is a form of physical training that
is delivered through virtual reality technology to facilitate motor learning and is efficacious in improving balance in
aged populations. In addition, studies have shown that anodal transcranial direct current stimulation (a-tDCS), when
applied to the primary motor cortex, can augment motor learning when combined with physical training. However,
no studies have investigated the combined effects of exergaming and tDCS on balance in people with PD.
Methods/design: Twenty-four people with mild to moderate PD (Hoehn and Yahr scale score 2–4) will be randomly
allocated to receive one of three interventions: (1) exergaming + a-tDCS, (2) exergaming + sham a-tDCS or (3) usual
care. Participants in each exergaming group will perform two training sessions per week for 12 weeks. Each
exergaming session will consist of a series of static and dynamic balance exercises using a rehabilitation-specific
software programme (Jintronix) and 20 minutes of either sham or real a-tDCS (2 mA) delivered concurrently.
Participants allocated to usual care will be asked to maintain their normal daily physical activities. All outcome
measures will be assessed at baseline and at 6 weeks (mid-intervention), 12 weeks (post-intervention) and 24
weeks (3-month follow-up) after baseline. The primary outcome measure will be the Limits of Stability Test.
Secondary outcomes will include measures of static balance, leg strength, functional capacity, cognitive task-
related cortical activation, corticospinal excitability and inhibition, and cognitive inhibition.
Discussion: This will be the first trial to target balance in people with PD with combined exergaming and a-tDCS. We
hypothesise that improvements in balance, functional and neurophysiological outcome measures, and neurocognitive
outcome measures will be greater and longer-lasting following concurrent exergaming and a-tDCS than in those
receiving sham tDCS or usual care.
Trial registration: Australian New Zealand Clinical Trials Registry, ACTRN12616000594426). Registered on 9 May 2016.
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Background
Parkinson’s disease (PD) is a chronic neurodegenerative
disorder that affects approximately 1% of adults aged
60 years and older worldwide [1–3]. A prominent motor
symptom of PD is postural instability, which typically
worsens as the disease progresses, leading to impaired
balance and increased risk of falls [4, 5]. The percentage of
people with PD who experience a fall ranges from 46% to
55% [6–8], with falls contributing to injury, loss of inde-
pendence and reduced quality of life (QoL) [5, 8–11]. Ex-
ercise is an effective treatment for improving balance in
people with PD [4–7], and ongoing exercise training can
be achieved through home-based training [8].
Exercise-based video gaming (exergaming) and immer-
sive virtual reality modes have been used as part of
home-based rehabilitation programmes to improve bal-
ance [9], and they may be as effective as conventional
balance training in people with PD [10]. Exergaming
combines physical movement with motion capture tech-
nology (e.g., Kinect®, Microsoft, Redmond, WA, USA;
Wii®, Nintendo, Kyoto, Japan) to generate an on-screen
avatar, which mimics the participant’s movements in real
time. This is known as gesture-based interaction training
[11], which combines automated game instructions as
well as auditory and haptic inputs to correct perform-
ance and sustain motivation levels during and following
game play [12–14]. For example, exergames for rehabili-
tation can provide auditory instructions to improve
patient performance, such as ‘stand tall’ or ‘place your
feet wider’, allowing patients to recognise deficits in
movement and self-correct in real time [10, 15]. In
addition, given that people with PD are dependent on
sensory cues to overcome postural instability [16, 17],
exergames employ visual and auditory feedback (termed
biofeedback) techniques to create a quasi-immersive en-
vironment which can facilitate motor and cognitive
learning [12, 18–22].
People with PD have difficulties with the long-term
consolidation of new motor skills [23], but adjunctive
neuromodulatory techniques, such as non-invasive brain
stimulation, may help to upregulate neuroplasticity and
facilitate motor skill acquisition and retention [24].
Transcranial direct current stimulation (tDCS) is a
therapeutic tool that has been used to attenuate motor
symptoms of PD [24, 25] with few side effects (e.g., occa-
sional headache/nausea and scalp itchiness) [24]. When
applied to the primary motor cortex (M1), anodal tDCS
(a-tDCS) can induce a lasting increase in M1 excitability
and reduce cortical inhibition, resulting in improved
functional performance [26]. When combined with other
training modalities such as exercise or physical therapy,
greater and longer-lasting improvements in motor func-
tion have been observed in healthy and clinical popula-
tions than with either treatment modality alone [27–29].
However, no studies have investigated the concurrent
use of a-tDCS and exergaming in people with PD.
The aims of this study are to determine the effects of a
12-week concurrent exergaming and a-tDCS intervention
on measures of static and dynamic balance and to evaluate
any long-term residual effects. Additionally, we will em-
ploy transcranial magnetic stimulation (TMS) techniques
in the M1 and functional near-infrared spectroscopy
(fNIRS) in the left and right dorsolateral pre-frontal
cortices (DLPFC) to determine neurophysiological mecha-
nisms that may underpin changes in balance. We hy-
pothesise that the combination of exergaming and a-tDCS
will lead to greater and longer-lasting improvements in
balance and neurophysiological measures than exergam-
ing or usual care alone.
Methods/design
We will conduct a 24-week, exploratory, double-blind,
randomised controlled trial to investigate the effects of a
concurrent exergaming and a-tDCS intervention that
includes a 12-week post-intervention follow-up period.
Participants will be randomly allocated to one of three
groups: (1) exergaming + a-tDCS, (2) exergaming +
sham a-tDCS or (3) usual care (control). The trial will
be conducted at the Institute for Physical Activity and
Nutrition at Deakin University, Burwood, Melbourne,
Australia. Ethical approval was granted by the Deakin
University Human Research Ethics Committee (project
number 2016-053), and the trial is registered with the
Australian New Zealand Clinical Trials Registry
(ACTRN12616000594426).
Participants
A total of 24 men and women aged 55 years and older
who have been diagnosed with mild to moderate PD
(Hoehn and Yahr scale scores 2–4) will be invited to par-
ticipate in this study.
Recruitment
A list of people with PD will be compiled from an exist-
ing research study database at Deakin University and in-
vited by telephone to participate in this trial. PD support
groups within inner and outer suburban Melbourne will
also be approached via mail or telephone to attend a
study information seminar, which will be delivered by a
member of the research team. All interested support
group members will receive additional information pam-
phlets. Study advertisements will also be placed in the
Australian Parkinson’s Disease Registry, in local newspa-
pers and on noticeboards at community libraries. All
participants who express an interest in the study will
first be screened over the telephone, and eligible partici-
pants will then be required to come to Deakin University
for additional screening as outlined below.
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Screening and eligibility
Telephone screening
All potential participants will be screened first over the
telephone and will be eligible for this trial if they meet
the following criteria: (1) have been diagnosed with PD
by a neurologist, (2) have experienced one or more falls
in the last 12 months, and (3) are not performing any
regular physical therapy or structured exercise training.
Participants will be ineligible based on the following
criteria: (1) severe lower limb motor impairments and/or
requirement of a walking aid or wheelchair, (2) previ-
ously diagnosed with stroke or dementia, (3) having
metal implants in the head (i.e., deep brain stimulator or
aneurysm clips), or (4) any other known medical, mental
health or physical condition which may interfere with
balance. Last, all participants need to be on a stable
medication regimen for more than 6 weeks before pro-
ceeding to the on-site screening session.
On-site screening
The on-site screening session will be held at Deakin Uni-
versity, Burwood campus. During this session, participants
will be required to complete the Montreal Cognitive As-
sessment, which is a 30-point screening instrument that
assesses mild cognitive impairment (MCI). A cut-off score
< 26 of 30 indicates the presence of MCI and will exclude
participants from this trial [16, 30]. Participants will also
be assessed using the motor section of the Unified Parkin-
son’s Disease Rating Scale (UPDRS), and individuals will
be deemed eligible for the study only if they have mild to
moderate PD (Hoehn and Yahr scale scores 2–4). All
eligible participants will then be given a plain-language
statement and consent form to sign and return prior to
commencing the programme.
Randomisation
Randomisation will be performed by a researcher inde-
pendent from the study using computer-generated ran-
dom numbers (Excel software; Microsoft). A flow diagram
of the study protocol is provided in Fig. 1.
Familiarisation
Following enrolment in the study and randomisation,
participants will be asked to attend a familiarisation
session at Deakin University. During this session partici-
pants allocated to the intervention groups will briefly
practise all testing and intervention procedures. Partici-
pants allocated to the control group will only briefly
Fig. 1 Consolidated Standards of Reporting Trials (CONSORT) flow diagram of eligibility screening to the final follow-up assessment. tDCS Transcranial
direct current stimulation
Harris et al. Trials  (2018) 19:387 Page 3 of 13
undertake the testing procedures. As part of the inter-
vention familiarisation procedure, all participants will
perform a single set of each exergame while the objec-
tives of each exergame are explained to them.
Allocation and blinding
Following their enrolment in the study and after baseline
testing, participants will be randomly allocated to one of
three groups: (1) exergaming + a-tDCS, (2) exergaming
+ sham tDCS group or (3) a usual care control group.
All groups will be stratified by sex to ensure equal distri-
bution of male and female participants between groups.
A researcher independent from the research team will
pre-allocate a code for either real or sham a-tDCS, and
the code will be given to the attending researcher to be
input into the tDCS device during each training session.
The identity of each code will be known only by the in-
dependent researcher to ensure double-blinding of both
the attending researcher conducting the training session
and the participant.
Intervention
The training intervention will be conducted over a
12-week period and will consist of exergames using an
augmentative virtual reality software (Jintronix, Montreal,
QC, Canada) with concurrent a-tDCS. Participants will be
required to attend training sessions at Deakin University,
Burwood campus, twice per week on non-consecutive
days (24 training sessions in total). The exergaming train-
ing sessions will be supervised by the attending researcher
and will last approximately 30 minutes. Jintronix rehabili-
tation software, which contains over 100 rehabilitation
exergames, along with a three-dimensional motion cap-
ture sensor (Kinect®), will be used in this study. The exer-
games performed by the participants will be pre-selected
by the attending researcher and tailored to each partici-
pant’s physical needs. The participant’s programmes will
include exercises that focus on multiple domains of bal-
ance, including bilateral weight transfer, unilateral balance
ability, trunk mobility and transitional activities (e.g.,
standing from a chair). An example balance training
programme is illustrated in Fig. 2.
The exergames will be projected on a wall-mounted flat
screen television via a laptop (Fig. 3). The attending re-
searcher will provide standardised verbal feedback to en-
courage performance throughout each exergaming session.
As an embedded feature of each exergame, a completion
score will be provided to the participant on-screen, which
will represent their performance; for example, a score of
five of ten gates achieved in the downhill ski exergame indi-
cates a 50% success rate. The training sessions will be pro-
gressed manually by the attending researcher by increasing
the difficulty of each exergame. Gaming progression will be
based on the participant’s capacity to consistently achieve a
score of 80% over two consecutive sessions.
A tDCS Stimulator Model 101 (TCT Research Ltd.,
Kowloon, Hong Kong, China) will be used to deliver real
and sham a-tDCS concurrently during exergaming using
rubber electrodes (50 mm× 70 mm) placed on the scalp
over the M1 to the area which best represents the lower
limb (Fig. 3). The optimal lower limb motor representa-
tion will be pre-determined by TMS during baseline test-
ing. A midline monopolar anode-electrode montage will
be adopted [31], with the cathode placed on the trapezius
muscle at the midpoint between the occipital protuber-
ance and acromion process/lateral portion of the scapula
spine. For a-tDCS, the intensity will be incrementally in-
creased over the initial 30 seconds to 2 mA and then
maintained at that intensity for the duration of the train-
ing. Sham a-tDCS will include a 30-second ramp phase to
2 mA to provide sensory stimulation similar to that of real
anodal tDCS before returning to baseline. This method of
sham stimulation has been used successfully in a-tDCS to
blind the participant and attending researcher to the
stimulation condition [25, 32]. To ensure double-blinding
of the participant and experimenter administering tDCS,
blinding codes will be provided to the experimenter prior
to the start of the session that activates either the sham or
active a-tDCS option.
Usual care
Participants assigned to the control group will be
instructed to continue to receive their usual care from
their medical practitioner and community services. In
addition, usual care participants will be asked to refrain
from partaking in any physical exercise training for the
duration of the intervention (i.e., 24 weeks from baseline
testing) other than their usual activities of daily living.
Upon completion of the follow-up assessment, usual
care participants will be offered advice about exercises
from the attending researcher.
Outcome measures
A summary of all outcome measures collected at each
time point is shown in Fig. 4 (also see Additional file 1:
SPIRIT checklist). All outcome measures will be taken at
four time points: baseline (week 0), mid-intervention (6
weeks), post-intervention (12 weeks) and follow-up (24
weeks). The mid- and post-intervention testing sessions
will occur within 72 hours, but no less than 24 hours,
following the preceding training session.
Primary outcome measure
Dynamic posturography
The primary outcome will be dynamic balance, which will
be measured using the Limits of Stability Test (LOS) de-
livered through a dynamic computerised posturographic
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device (NeuroCom SMART Balance Master; Natus Med-
ical, Inc., Pleasanton, CA, USA). The NeuroCom SMART
Balance Master consists of two movable force platforms
mounted with five strain gauges (100-Hz sampling rate)
sensitive to vertical and horizontal shear forces and a vis-
ual surround designed to prevent peripheral visual fixation
[33]. The force plate and visual surroundings are designed
to tilt in an anterior-posterior plane during various testing
conditions. A telemonitor mounted on the visual sur-
round provides instructions for each test in addition to
visual feedback of the participant’s foot position and
movement during the test [33]. The participants will be
asked to stand barefoot on the centre of the force plat-
form. Participants will be fitted into a support harness
throughout the test to prevent a fall occurring. The two
posturographic tests to be performed on the NeuroCom
Fig. 2 Example exergaming programme to improve balance
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SMART Balance Master are the LOS and the Sensory
Organization Test (SOT), which is a secondary outcome
measure. The LOS requires each participant to purpose-
fully move their centre of pressure (COP) towards an
intended target in the following order: forward, forward
right, right, backward right, backward, backward left,
left and forward left [27]. Movement velocity (degrees
per second), maximal excursion (greatest distance
[cm] achieved towards the intended target/maximal
distance of target [cm]) and directional control ([the
amount of intended movement − amount of extrane-
ous movement)/amount of intended movement] × 100)
will be measured. The LOS has shown excellent
test-retest reliability for movement velocity (intraclass
correlation coefficient [ICC] = 0.825) and sway path
length (0.846) [34].
Secondary outcome measures
Static posturography
The SOT comprises six different sensory conditions in
quiet stance and measures the COP path in centimetres.
The test begins with condition 1 (eyes open in a quiet
stance) and sequentially moves through each condition,
which progressively becomes more challenging by either
distracting or removing visual and/or proprioceptive
feedback. The visual surround and force platform are
sway-referenced, which refers to the tilting of the sup-
port surface and/or visual surround in response to
movement of the participant’s COP. During the
sway-referenced conditions, erroneous sensory informa-
tion is presented to discombobulate the participant while
the force platform measures the participant’s ability to
compensate by using other senses to maintain balance
equilibrium. The following are the six sensory
conditions:
1. Condition 1: Eyes open and fixed support
2. Condition 2: Eyes closed and fixed support
3. Condition 3: Eyes open sway-referenced and
support sway-referenced
4. Condition 4: Eyes open and support sway
referenced
5. Condition 5: Eyes closed and support sway-
referenced
6. Condition 6: Eyes open and sway-referenced with
support sway-referenced
The composite equilibrium score, presented as a
weighted average percentage of the six conditions, will be
used to determine overall static balance performance and
has shown good reliability (ICC = 0.67) [35]. Additionally,
the sensory analysis ratios obtained from specific sensory
test condition pairs will be used to determine the level of
reliance on different senses to maintain balance equilib-
rium [36]. The following ratios will be used:
 Somatosensory ratio ([SOT2/SOT1] × 100) will
measure the participant’s reliance on the
somatosensory system to maintain balance
equilibrium.
 Visual ratio ([SOT4/SOT1] × 100) will measure the
participant’s reliance on the visual system to
maintain balance equilibrium.
 Vestibular ratio ([SOT5/SOT1] × 100) will measure
the participant’s reliance on the vestibular system to
maintain balance equilibrium.
 Visual preference ratio ([SOT 3 + 6/SOT 2 + 5] ×
100) will measure the participant’s reliance on visual
information, even when the information is incorrect,
to maintain balance equilibrium.
Participants will have only a single practise trial for
each sensory condition to minimise any practise effect
between testing protocols. If the participant requires as-
sistance or takes a considerable step away from the force
plate, it will be registered as a loss of balance, and an
equilibrium score of zero will be indicated.
Fig. 3 Example of anodal transcranial direct current stimulation montage (a) and exergaming set-up using Jintronix software (b)
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Transcranial magnetic stimulation and electromyography
Single- and paired-pulse TMS of the M1 will be conducted
using a BiStim2 2002 magnetic stimulator (Magstim Co.,
Whitland, UK) to measure changes in corticospinal excit-
ability and intracortical inhibition of the tibialis anterior
(TA) muscle. The TA was selected as the target muscle
Fig. 4 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT 2013) diagram illustrating the schedule of enrolment, post-
allocation and close-out for all assessments. TMS Transcranial magnetic stimulation, fNIRS Functional near-infrared spectroscopy, UPDRS Unified
Parkinson’s Disease Rating Scale, mBEST Mini Balance Evaluation Systems Test, 4SST Four Square Step Test, 5TSTST Five Times Sit to Stand Test,
10MWT 10-Metre Walk Test, PDQ-39 39-Item Parkinson’s Disease Questionnaire
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because it is primarily involved with postural balance [37].
Prior to TMS, all participants will wear a custom-made
nylon cap marked with a 1-cm concentric grid that extends
outward from the vertex. A double-cone TMS coil with a
wingspan of 110 mm will be positioned directly over the
vertex of the head, and the optimal site of stimulation will
be determined by initial exploration around the vertex that
produces the largest and most consistent motor-evoked po-
tential (MEP) recordings from the TA. Once the optimal
site of stimulation has been identified, the resting motor
threshold (RMT) will be determined. The RMT is defined
as the lowest TMS intensity that produces an average MEP
amplitude between 50 and 100 μV in response to five of
ten stimuli [38]. Ten single-pulse TMS stimuli will then be
delivered at 80%, 100%, 120%, 140% and 160% of RMT
each to establish a stimulus-response curve that will be
used to measure changes in corticospinal excitability with
excellent reliability (ICC = 0.986) [38].
Corticocortical inhibitory circuits are suppressed in
people with PD [39], and therefore paired-pulse TMS will
be used to determine changes in short-interval/long-inter-
val intracortical inhibition (SICI/LICI). Paired-pulse TMS
will be delivered using a conditioning stimulus-test stimu-
lus paradigm separated by a set interstimulus interval
(ISI), which has shown excellent reliability (ICC = 0.934)
[38]. To measure SICI, the CS will be set at 0.8 RMT,
whereas the TS will be set at 1.2 RMT, separated by an ISI
of 3 milliseconds [40]. For LICI, both the CS and TS will
be set at 1.2 RMT, separated by an ISI of 100 milliseconds
[41]. To calculate SICI and LICI, ten conditioned and un-
conditioned TS at the respective ISIs will be delivered and
expressed as a percentage change of the average condi-
tioned to unconditioned TS response. Surface electro-
myography (sEMG) can detect the level of muscle activity
induced from transcranial stimulation and will be re-
corded using two bipolar Ag-AgCl electrodes 2 cm apart
over the muscle belly of the TA and a ground electrode
placed over the patella [42]. Prior to applying the elec-
trodes, the participant’s skin will be shaved and swabbed
with alcohol. All sEMG signals will be amplified (× 1000)
with band-pass filtering between 5 Hz and 500 Hz, sampled
at 4000 Hz and collected via a laboratory analog-digital
interface (PowerLab 8/30; ADinstruments, Bella Vista,
Australia) for later offline analysis.
Cognitive function
E-Prime software (Psychology Software Tools, Sharps-
burg, PA, USA) [43] will be used to design two fNIRS-
compatible computer-based cognitive assessments using
a three-block design with a 30-second task period offset
with a 30-second rest period. The Stroop colour-word
test and the Go/No-Go test will be used to assess execu-
tive function, in particular response inhibition, interfer-
ence control, attention and choice reaction time. In the
Stroop colour-word test, participants will be presented
with two conditions: incongruent and congruent. The in-
congruent condition will randomly present two colour
words (red and green) written in opposing ink colours (e.g.,
the word ‘red’ will be written in green ink). For the congru-
ent condition, the word and ink colour are the same (e.g.,
the word ‘red’ will be written in red ink). Upon presentation
of the word, the participant must strike the key indicating
the colour of the word presented, and the response time
will be recorded in seconds. Cognitive central processing
ability will be determined by measuring the difference in re-
sponse times between the two conditions [29].
The Go/No-Go task is a choice reaction time test that
requires participants to either strike or delay striking the
left mouse button during two separate conditions (go and
no-go). In the ‘go’ condition, the participants will be pre-
sented with a random series of letters and will be asked to
strike the left mouse button as fast as they can as each let-
ter appears. In the ‘no-go’ condition, a further random
series of letters will appear; however, the participant will
be asked to delay striking the mouse only when the letter
‘X’ appears. The reaction time for each response during
each condition will be recorded in seconds.
Functional near-infrared spectroscopy
fNIRS is a non-invasive and portable neuroimaging tech-
nique that uses near-infrared light which penetrates the
skull to detect changes in oxygenated haemoglobin
(O2Hb) and deoxygenated haemoglobin (HHb) concen-
trations within the cortical microcirculation, such as the
capillary, arteriolar and venular beds. fNIRS will be used
in conjunction with the Stroop and Go/No-Go tasks to
measure task-related changes in DLPFC activation.
Task-related changes in fNIRS haemodynamic response
activation show adequate to high reliability (ICC = 0.42–
0.87) [44] and have been validated against the gold
standard functional magnetic resonance imaging (fMRI)
blood oxygen level-dependent response [45, 46].
A multi-channel continuous-wave fNIRS system (OxyMon
Mk III; Artinis Medical Systems, Elst, The Netherlands) will
be used to measure task-related changes in O2Hb and HHb
concentrations in the left and right DLPFC during the
Stroop and Go/No-Go tasks [47, 48]. An eight-channel
fNIRS optode montage will be used (four channels on each
hemisphere), and each transmitter and receiver optode pair
will be placed between 30 mm and 40 mm apart for optimal
near-infrared light penetration into the cortical layer.
Oxysoft data acquisition software (Artinis Medical Sys-
tems) will be used for fNIRS data collection and analysis.
The modified Lambert-Beer law, assuming constant scat-
tering [49], will be adopted to detect concentration
changes of O2Hb and HHb in the left and right DLPFC,
dependent on the changes in detected light intensity. For
analysis, O2Hb and HHb signals of the four channels of
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each hemisphere will be averaged. The moving SD based
artefact removal method will be used within each trial to
remove movement artefacts and other noise from the
fNIRS signals [50]. The thresholds for artefact detection
will be set to 0.45 for O2Hb and 0.18 for HHb [51], with a
window length for moving SD calculation at 0.5 seconds,
and a window length for artefact correction (LOESS
smoothing window) at 1 second. The fNIRS signals will
then be linearly de-trended per trial and low-pass-filtered
at 0.1 Hz to remove heart rate and other high-frequency
physiological signals. To enable direct comparison of the
different trials within each task, the filtered signals will be
biased using the average concentration of the 5 seconds
before the “start” instruction as a reference (zero). Then,
individual trials will be averaged per task to create three
mean time-course signals per person, which will then be
averaged over all participants. Last, the peak and mean
concentrations of O2Hb and HHb will be calculated over
all trials for all participants and then averaged for each of
the tasks.
Quality of life
The 39-item Parkinson’s Disease Questionnaire (PDQ-
39) is a valid and reproducible PD-specific measure of
QoL [52, 53]. Each question is based on a 5-point or-
dinal scoring system ranging from 0 = never to 4 =
always. There are eight dimensions, with each dimension
score being the sum score of each item in the dimension
divided by the maximum possible score of all the items
in the dimension, multiplied by 100. The overall score is
known as the Parkinson’s disease summary index and is
the sum of all dimension total scores divided by 8.
Functional assessments
The UPDRS, Mini Balance Evaluation Systems Test
(mBEST), Five Times Sit to Stand Test (5TSTST),
10-Metre Walk Test (10MWT), Four Square Step Test
(4SST) and maximal lower limb strength (one-repetition
maximum [1RM] leg press) will be used to assess
disease-related motor function and lower extremity
physical function. Each of these tests will be performed
in the same order each time with the participants wear-
ing their own footwear and will be conducted by the at-
tending researcher.
Section III of the UPDRS will be used to measure
disease-related motor function and has shown excellent
reliability (ICC = 0.90) [54]. The UPDRS comprises 33
scores based on 18 questions with several right, left or
other body distribution scores.
The mBEST is a reliable tool (ICC = 0.92) [55] that
assesses four domains of dynamic balance, including
anticipatory postural adjustments, reactive postural con-
trol, sensory orientation and dynamic gait. The testing
series consists of 14 tests, with each of the 14 items rated
on a 3-level ordinal scale (ranging from 0 = cannot per-
form/severe, to 2 = normal) for a total score of 28 points.
For the two items that are assessed bilaterally, the lower
score will be used for the composite score. A cut-off score
of 20 of 28 will be used to distinguish participants as ‘at
risk’ for falls [55].
The 5TSTST will be used to determine functional
lower limb power and has excellent test-retest reliability
for people with PD (ICC = 0.91) [56]. Participants begin
the 5TSTST test sitting in an armless chair with a height
of 45 cm [34]. The participants will be instructed to
cross their arms over their chest and sit with their back
against the upright back-rest of the chair, with their feet
placed flat on the floor and their knees at 90 degrees.
They will then be instructed to quickly and repeatedly
rise to a full standing position and then sit back down
on the chair for five repetitions. A single repetition will
be defined as a vertical standing position with an upright
trunk and with the hips and knees extended. The test
will begin once the participant moves off the chair for
the first stand and will finish once the participant sits
following the fifth sit-to-stand repetition, with the total
time to completion recorded in seconds.
The 10MWT will be used to determine gait speed and
has shown excellent test-retest reliability for comfortable
gait speed (ICC = 0.96) and maximum gait speed (ICC =
0.97) for people with PD [57]. The test is set up with
two cones positioned 10 m apart, with two more cones
positioned at the 2-m and 8-m marks. The participant is
instructed to walk the entire 10 m, but only the time
from the moment the participant reaches the 2-m cone
to the moment they reach the 8-m cone (distance of
6 m) is recorded to accommodate for acceleration and
deceleration periods. Each participant will perform three
trials at two different walking speeds: comfortable speed
and fast speed. Each trial will be separated by a
1-minute rest period, and each trial will be recorded in
seconds. The average speed in metres per second will be
calculated and used for analysis [57].
The 4SST will be used to determine dynamic balance
and stepping speed in four directions [58]. The 4SST has
shown excellent test-retest reliability (ICC = 0.98) for
people with PD [59]. Participants will be asked to step
forwards, sideways and backwards over two metal rods
positioned flat on the floor in a cross formation. The test
begins with the participant moving first in a clockwise
direction and returning in a counter-clockwise position
to the start square. Participants will be asked to step
with two feet into each square without touching or step-
ping on the rods as quickly as possible. A practise trial
will be performed first, followed by two true attempts,
which will be recorded with a stopwatch. The fastest
time of completing the sequence in seconds will be used
for analysis.
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Functional strength of the lower limb
Lower extremity strength will be assessed using a 1RM leg
press, which has previously shown excellent test-retest re-
liability for people with PD (ICC = 0.87–0.98) [60] and will
be conducted using fixed pneumatic leg press (Air300;
KEISER, Fresno, CA, USA). Ten warm-up repetitions will
be performed prior to any near-maximal effort. The par-
ticipant will then perform a near-maximal repetition (esti-
mated at 80% of their 1RM) while maintaining correct
technique, following which the resistance will be incre-
mentally increased by 5–10% as appropriate, until the par-
ticipant can no longer perform a full repetition [61]. Three
minutes’ rest will separate each maximal attempt, and ver-
bal encouragement will be provided. The highest resist-
ance used to perform a successful repetition will be
recorded as the 1RM in kilogrammes.
Additional measures
Height will be measured to the nearest 0.1 cm using a
standardised portable stadiometer. Weight will be mea-
sured to the nearest 0.1 kg using a standardised set of
scales. Both height and weight will then be used to cal-
culate body mass index in kilogrammes per metre
squared. To ensure consistency of the data collection,
participants will be instructed to wear light-fitting
clothes and remove loose items before standing barefoot
while having their height and weight recorded. Finally,
interviews will be conducted with participants to moni-
tor habitual physical activity and to establish any medi-
cation (in addition to PD-related medication) that they
may be taking throughout the length of the intervention.
Exercise compliance
Participants will be required to complete a minimum of
20 of the 24 scheduled training sessions (representing >
85% attendance) within the entirety of the 12-week inter-
vention period. If sessions are missed, participants will be
given an opportunity to complete additional sessions to
make up for the missed sessions. This completion per-
centage is typical of large community-based exercise inter-
vention studies and meets standard expectations of
per-protocol analysis [62]. Compliance will be recorded
using attendance sheets, which will be filled out by the at-
tending researcher after each training session.
Adverse events
The attending researcher will discuss what an adverse
event (AE) is with each participant before the intervention
begins. For this trial, an AE will be defined as any un-
favourable and unintended sign, symptom or disease
temporarily associated with the intervention (either exer-
gaming or a-tDCS), without any understanding about
causality or relationship to the therapy. The attending
researcher will ask each participant before training begins
about any AEs experienced and will document all AEs
associated with the intervention. Usual care participants
will be phoned and asked fortnightly about any experi-
enced AEs. All AEs will be reported following the guide-
lines recommended by the National Health and Medical
Research Council position statement (https://www.nhmr
c.gov.au/guidelines-publications/e112). All participants will
be asked to contact the attending researcher immediately
after experiencing an AE, which will be recorded and
promptly reported to the chief investigator, who will then
determine its seriousness and causality in conjunction with
any medical staff attending the event. Any AEs that are
related to any part of the intervention will be reported to
the Deakin University Human Research Ethics Committee.
Sample size calculation
On the basis of data provided by Shih et al. [31], whose
primary outcome was the LOS to assess reaction time
and excursion endpoints in people with PD (Cohen’s d
= 0.74, 77% improvement in reaction time, 89% improve-
ment in endpoint excursion), a sample size calculation
using G*Power statistical software estimated a sample
size of five participants per group would be sufficient for
85% power (α = 0.05) while using a conservative esti-
mated SD change of ± 5. It is difficult to determine if
this is a large-enough sample size to detect change
between the real and sham a-tDCS conditions, given the
paucity of literature using a testing paradigm of exercise
+ real a-tDCS vs exercise + sham a-tDCS vs control.
However, using the percentage changes between real and
sham conditions reported by Kaski et al. [28], we postu-
late that a sample size of 18 participants will be enough
to detect a medium effect size between the real and
sham a-tDCS groups (Cohen’s d = 0.5) with an estimated
SD change of ± 25 for the retropulsion pull test. The
LOS and SOT measures were not used by Kaski et al.
[28]; therefore, the retropulsion pull test was selected
because it contains a balance perturbation similar to that
of the SOT. Therefore, to accommodate for a 20%
dropout rate, we aim to recruit 8 participants per group
(24 participants in total).
Statistical analysis
Statistical analyses will be conducted using Stata version
11 statistical software (StataCorp, College Station, TX,
USA). A generalised linear mixed model with factors for
time (0, 6, 12 and 24 weeks), group (exergaming + sham
a-tDCS vs exergaming + real a-tDCS vs control) and
group-by-time interaction will be used to determine the
effect that different direct current stimulation interven-
tions have on brain excitability and balance. Potential
factors such as the participant’s age and time since
diagnosis will be used as covariates for analyses within
our models. Per-protocol analysis will also be performed
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by including all participants who are at least 85% com-
pliant with the exercise (as measured by the number of
exercise sessions attended). Post hoc analyses using the
Bonferroni correction will be applied as appropriate.
Pearson’s product-moment correlation coefficient will be
used to measure the level of correlation between change
scores of the functional tests and brain excitability and
activation. Significance will be set at P < 0.05.
When possible, we will try to obtain all endpoint mea-
sures from any dropouts in the final analysis. For partici-
pants who are lost to follow-up, missing data will be
handled using the multiple imputation method [63]. Be-
cause the multiple imputation method assumes only that
data are missing at random [64], we will additionally per-
form sensitivity analyses to evaluate the potential effect of
non-random attrition [65]. Sensitivity analyses will involve
testing a range of plausible scenarios in outcomes for par-
ticipants who were lost during follow-up [66].
Discussion
Falls among people with PD incurs a considerable cost as-
sociated with hospitalisation and injury management or
treatment. An economic report published in 2014 estab-
lished that health system costs due to accidental falls rep-
resent an additional 22% of the total health cost of PD
[67]. This translates to an additional estimated annual cost
of $1487AUD per person with PD [67]. Exergaming is a
mode of exercise that is engaging, adds diversity to a re-
habilitation programme, can be performed at home and
may be effective at improving functional capacity and re-
ducing risk of falls in people with PD. However, by com-
bining exergaming with a-tDCS (a primer for adaptive
neuroplasticity), greater and longer-term improvements in
motor function may be achieved. To date, there is limited
evidence for the effectiveness of combined exergaming
and a-tDCS to improve balance and lower limb function
in people with PD. As such, we aim to use a double-blind,
randomised controlled study protocol to explore the effi-
cacy of concurrent a-tDCS and exergaming for improving
static and dynamic balance over a period of 12 weeks. In
addition, our secondary objectives of using TMS and
fNIRS to measure neurophysiological changes in the M1
and DLPFC will potentially provide a mechanistic under-
standing of any functional changes observed. Last, few
studies have addressed the consolidation of long-term
motor skill retention following exercise and a-tDCS in
people with PD, and therefore we aim to explore any re-
sidual improvements in balance, lower limb and/or neuro-
physiological function after a 12-week follow-up period.
In our study, exergames are used to deliver cognitive and
static and dynamic balance exercises for people with PD.
The Jintronix software used in our study is capable of using
an inexpensive, commercially available motion capture
camera to deliver a vast selection of rehabilitation games
from a personal computer or laptop. Additionally, the use
of a-tDCS to augment adaptive neuroplasticity may lead to
greater and longer-lasting improvements in balance and
lower limb function in people with PD. Thus, we hypothe-
sise that (1) balance will improve for the exergaming groups
compared with controls and (2) the addition of real a-tDCS
will provide additive improvements. Novel home care ther-
apies that are easily administered are likely to maintain ex-
ercise enjoyment and facilitate long-term exercise
adherence. Therefore, if this trial is successful, this interven-
tion will potentially allow for a high degree of scalability
into a community- or home-based setting, where
exergames can be implemented either as part of a re-
habilitation programme in health-care facilities (i.e., re-
habilitation hospitals, age care facilities and nursing
homes) or as an adjunctive therapy that can be per-
formed at home in conjunction with standard therapy.
Our study also has the potential to have wider implica-
tions for reducing total health-care costs (i.e., hospital-
isation, injury management and assistive care costs)
associated with falls for people with PD.
Trial status
Eighteen participants have completed 24 weeks of training
and are waiting to be tested at 3-month follow-up. No
dropouts or adverse events have been reported.
Additional file
Additional file 1: Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) 2013 checklist: recommended items to
address in a clinical trial protocol and related documents. (DOC 122 kb)
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